Investigation Report on China Rituximab Market, 2009-2018
DUBLIN, March 25, 2014 /PRNewswire/ –
Research and Markets (
http://www.researchandmarkets.com/research/7dhkqb/investigation) has announced the
addition of the “Investigation Report on China Rituximab Market, 2009-2018″
[http://www.researchandmarkets.com/research/7dhkqb/investigation ] report to their
Rituximab (trade names “”MabThera”" by Roche, “”Rituxan”" by Genetech) is a chimeric
monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very
effective and shows good tolerance in the treatment of B-cell lymphoma. As people
understand more about B-cell and its action mechanism, it is acknowledged that besides
B-cell malignancies rituximab can also treat autoimmune diseases such as rheumatoid
arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. Global
sales revenue of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million
from 2010 to 2012 respectively.
Statistics shows that incidence of non-Hodgkin lymphomas in China has increased
steeply from 20/1,000,000 at the end of the 20th century to 70/1,000,000 at present.
Autoimmune diseases can harm central nervous system and organs such as lung, liver and
kidney, leading to organ dysfunction and even organ failure. All of them can be
life-threatening. Statistics shows that there are approximately 30 to 40 million people
suffering from autoimmune diseases in China. Such high incidence should be taken seriously
by the public.
By the first quarter of 2014, there were no products from local manufacturers on the
market, which was completely occupied by Roche. Early 2014, monoclonal antibody drug
“”recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection”" produced by
Hisun was approved clinical. It is a generic drug of Roche’s monoclonal antibody
“”Rituximab”". Five manufacturers in China have reported clinical use of rituximab generic
drug. It is estimated that more generic drugs will go on the market in the next few years.
According to CRI’s investigation on certain sample hospitals in China, the CAGR of sales
value of rituximab surpassed 35% from 2005 to 2012. Rituximab is expected to have huge
room to grow in future Chinese market.
Key Topics Covered: 1 Relevant Concepts of Rituximab 2 Market Overview of Rituximab in China, 2009-2013 3 Investigation on Sales Value of Rituximab in China, 2009-2013 4 Investigation on Market Share of Major Rituximab Manufacturers in China, 2009-2013 5 Investigation on Market Size of Rituximab by Dosage Form in China, 2009-2013 6 Reference Price of Rituximab in China Hospital Market, 2014 7 Major Manufacturers of Rituximab in China Market 8 Prospect of China Rituximab Market, 2014-2018
- Hoffmann-La Roche - Roche Diagnostics - Shanghai Roche Pharmaceutical
For more information visit
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets